This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In clinicaltrials, the highest dose was set at 960 mg; whilst judged to be well-tolerated, 45 percent of patients receiving this dose showed serious complications and 7 percent had to stop treatment. Petra holds a D.Phil in synthetic organicchemistry and am MBA from Imperial College London.
Working in the CRO and CDMO environment she has led projects for customers across the globe, helping them to achieve their goals in clinicaltrials and low-volume commercial manufacture. Petra holds a D.Phil in synthetic organicchemistry and an MBA from Imperial College London.
After completing my PhD in organicchemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. These very large teams need to stay on track to hit delivery milestones for clinicaltrials. Photo credit: Jeff Dowling, EMBL-EBI What is your professional background?
A graduate of the Hebrew University of Jerusalem, he earned a Bachelor of Science in chemistry and physics and a Master of Science in physical organicchemistry before completing a Doctor of Philosophy in 1971. and Pure Tech Health. He also remains active as the chief executive officer and chairperson of AZTherapies Inc.
At Zymeworks we apply a holistic approach to optimise each of the ADC components, leveraging insights gained from clinicaltrials and real-world clinical experience to inform the design of novel ADCs. He has more than 17 years of experience in ADC and protein chemistry research and drug development.
Overall, only a few prodrugs for CNS disorders have even reached clinicaltrials , so for the most part traditional property-based drug design remains the best bet for the vast majority of programs. What is K p,uu ? Recently, Dennis helped advance programs on Chagas disease and Malaria as a project team leader.
Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content